Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories. MS ionizes chemical species and sorts the ions based on mass to charge ratio. It can be used in various fields, applied to pure samples and complex mixtures. According to a recent research published by P&S Market Research, the global MS market accounted for $4.9 billion revenue in 2015, and it is expected to grow at a CAGR of 8.1% during 2016-2022, crossing the $7.3 billion mark by 2022.
The global MS market is witnessing high growth rate thanks to technological advancements in mass spectrometers and continuously increasing expenditure on healthcare around the world. Besides clinical testing, the MS analytic technique can be used for drug discovery and development, proteomics (the study of proteins), and also detecting of microorganisms in food helping to quality control and food safety. The market potential behind the technique is reflected in its contribution to the quality of patient care. Along with that, improvements in analytical performance in areas such as toxicology, endocrinology, and biochemical genetics.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a life sciences company focused on the development and commercialization of a novel platform technology called Pressure Cycling Technology (PCT), designed to control bio-molecular interactions. The company’s instrument, the Barocycler, and the ProteoSolveLRS kit for the detergent-free extraction of proteins from lipid-rich samples, together make up the PCT Sample Preparation System. This system can be used for a wide range of applications including, sample preparation for genomic, proteomic, and small molecule studies, protein purification and much more.
Pressure BioSciences, Inc. recently announced an exclusive co-marketing agreement with SCIEX, a company focuses on science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR). Under the agreement, the companies will jointly promote Pressure BioSciences’ PCT-based sample preparation systems and SCIEX’s mass spectrometry equipment, with a focus on improved sample preparation. SCIEX has a particular interest proteomics, which is why a partnership with Pressure BioSciences might be productive.
SCIEX’s expertise in mass spectrometry provides marketing personnel and a worldwide distribution network that Pressure BioSciences, Inc. needs and will utilize. The co-marketing agreement will act to introduce Pressure BioSciences and its technology platform.
In the latest quarterly financial report, the company reported a 55.8% increase in revenue and a 13.4% decrease in operating costs, despite an increase in its marketing and sales efforts. Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We believe these and other recent successes have positioned us well for continued growth and future profitability. However, much remains to be done. It is important that we continue to build upon these recent successes. In that vein, it is imperative that we expand and enhance our current financial, operational, and technical capabilities, and that we find additional ways to help ensure that our progress is seen and understood by the worldwide financial and investor communities. To that end, we are committed to using funds from the PIPE Financing, Line-of-Credit, and Product Sales to help achieve these very important and timely goals. This may include, among other things, additions to staff, independent agents, distributors, and consultants focused primarily in sales and marketing,
Qiagen NV (NASDAQ: QGEN) and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. The company has a wide variety of products under its portfolio, among them is the Qproteome FFPE Tissue Kit, which enables efficient extraction of full-length proteins from FFPE tissues. Qiagen put an emphasis on investigating the suitability of proteins isolated using the Qproteome FFPE Tissue Kit for mass spectrometric (MS) analysis. The company revealed that a total of 635 unique peptides (frozen sample) and 567 unique peptides (FFPE sample) were isolated and identified by the MS technique.
Thermo Fisher Scientific Inc. (NYSE: TMO) is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company owns an exclusive Thermo Fisher Scientific workflow solution for proteins and peptides, which is enabled through proprietary MSIA D.A.R.T.’S™ technologies and designed to improve hybrid mass spectrometry bio-analysis, specifically biologic and biomarker bio-analysis.
Illumina Inc. (NASDAQ: ILMN) offers sequencing and array-based solutions for genetic analysis. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals. The company has a long history of researching and applying mass spectrometry in its business operations, and has participated in or published extensive research papers as well as articles on the potential benefits of the MS analysis technique. One such article was called, “Predicting immunogenic tumor mutations by combining mass spectrometry and exome sequencing.”